Article Versions Notes

Ruigrok EAM, Verkaik NS, de Blois E, de Ridder C, Stuurman D, Roobol SJ, Van Gent DC, de Jong M, Van Weerden WM, Nonnekens J. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment. International Journal of Molecular Sciences. 2022; 23(14):8037. https://doi.org/10.3390/ijms23148037

Ruigrok, Eline A. M., Nicole S. Verkaik, Erik de Blois, Corrina de Ridder, Debra Stuurman, Stefan J. Roobol, Dik C. Van Gent, Marion de Jong, Wytske M. Van Weerden, and Julie Nonnekens. 2022. "Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment" International Journal of Molecular Sciences 23, no. 14: 8037. https://doi.org/10.3390/ijms23148037

Ruigrok, E. A. M., Verkaik, N. S., de Blois, E., de Ridder, C., Stuurman, D., Roobol, S. J., Van Gent, D. C., de Jong, M., Van Weerden, W. M., & Nonnekens, J. (2022). Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment. International Journal of Molecular Sciences, 23(14), 8037. https://doi.org/10.3390/ijms23148037